Symbols / CTSO Stock $0.65 +2.68% Cytosorbents Corporation
CTSO (Stock) Chart
About
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 40.69M | Enterprise Value | 63.49M | Income | -8.20M | Sales | 37.06M | Book/sh | 0.09 | Cash/sh | 0.10 |
| Dividend Yield | — | Payout | 0.00% | Employees | 129 | IPO | — | P/E | — | Forward P/E | inf |
| PEG | — | P/S | 1.10 | P/B | 6.89 | P/C | — | EV/EBITDA | -4.98 | EV/Sales | 1.71 |
| Quick Ratio | 1.42 | Current Ratio | 2.12 | Debt/Eq | 493.16 | LT Debt/Eq | — | EPS (ttm) | -0.13 | EPS next Y | 0.00 |
| EPS Growth | — | Revenue Growth | 0.90% | Earnings | 2026-05-13 | ROA | -19.44% | ROE | -96.39% | ROIC | — |
| Gross Margin | 71.48% | Oper. Margin | -43.87% | Profit Margin | -22.12% | Shs Outstand | 62.80M | Shs Float | 54.82M | Short Float | 3.50% |
| Short Ratio | 18.75 | Short Interest | — | 52W High | 1.39 | 52W Low | 0.50 | Beta | 1.48 | Avg Volume | 87.07K |
| Volume | 17.29K | Target Price | $5.25 | Recom | None | Prev Close | $0.63 | Price | $0.65 | Change | 2.68% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-26 | main | D. Boral Capital | Buy → Buy | $10 |
| 2026-01-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-12-16 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-11-14 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-11-14 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-16 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-20 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-08 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-07-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-05-02 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-03 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-04-01 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-02-25 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-13 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-01-03 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
- Cytosorbents (CTSO) Stock: Near Support? (Volatility Increases) 2026-04-20 - Continuation Pattern - UBND thành phố Hải Phòng ue, 21 Apr 2026 04
- Cytosorbents (CTSO) Stock: Near Support? (Volatility Increases) 2026-04-20 - Stock Picks - Xã Vĩnh Công ue, 21 Apr 2026 04
- CTSO (Cytosorbents Corporation) posts 4.1 percent Q4 2025 revenue growth as shares edge higher despite a wide EPS miss. - Macro Risk - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 17
- CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus Sun, 19 Apr 2026 17
- CytoSorbents says new ICU swap system cuts workload in critical care - Stock Titan hu, 19 Mar 2026 07
- CytoSorbents Receives Nasdaq Extension to Regain Compliance - The Globe and Mail Fri, 03 Apr 2026 07
- Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO) Before Long - Yahoo Finance Sat, 14 Feb 2026 08
- CYTOSORBENTS ($CTSO) Releases Q4 2025 Earnings - Quiver Quantitative Wed, 25 Mar 2026 07
- Cytosorbents Corporation 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CTSO) 2026-04-02 - Seeking Alpha hu, 02 Apr 2026 07
- What limits growth of Cytosorbents (CTSO) Stock | Price at $0.63, Up 3.44% - Verified Analyst Reports - Cổng thông tin điện tử Tỉnh Sơn La Wed, 08 Apr 2026 07
- Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan hu, 02 Apr 2026 07
- CTSO (Cytosorbents Corporation) shares rise 8.2 percent despite Q4 2025 earnings landing below consensus analyst estimates. - High Volatility - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 11
- CytoSorbents (NASDAQ: CTSO) 2025 loss narrows on modest revenue growth - Stock Titan Wed, 25 Mar 2026 07
- CytoSorbents reports Q4 and full-year 2025 revenue expectations - Investing.com Mon, 12 Jan 2026 08
- Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower - simplywall.st hu, 13 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
37.06
+4.12%
|
35.59
+14.51%
|
31.08
+5.88%
|
29.36
|
| Operating Revenue |
|
37.06
+4.12%
|
35.59
+14.51%
|
31.08
+5.88%
|
29.36
|
| Cost Of Revenue |
|
10.57
-1.27%
|
10.71
+17.26%
|
9.13
-34.57%
|
13.96
|
| Reconciled Cost Of Revenue |
|
10.57
-1.27%
|
10.71
+17.26%
|
9.13
-34.57%
|
13.96
|
| Gross Profit |
|
26.49
+6.45%
|
24.89
+13.36%
|
21.95
+42.52%
|
15.40
|
| Operating Expense |
|
40.73
-1.47%
|
41.34
-23.31%
|
53.90
+14.87%
|
46.93
|
| Research And Development |
|
5.08
-33.15%
|
7.61
-51.22%
|
15.59
+3.15%
|
15.12
|
| Selling General And Administration |
|
35.65
+5.67%
|
33.73
-11.94%
|
38.31
+3.15%
|
37.14
|
| General And Administrative Expense |
|
—
|
—
|
37.87
+1.98%
|
37.14
|
| Other Gand A |
|
—
|
—
|
37.87
+1.98%
|
37.14
|
| Other Operating Expenses |
|
—
|
—
|
-5.26
+1.21%
|
-5.33
|
| Total Expenses |
|
51.30
-1.43%
|
52.05
-17.43%
|
63.03
+3.53%
|
60.88
|
| Operating Income |
|
-14.24
+13.45%
|
-16.45
+48.50%
|
-31.95
-1.35%
|
-31.52
|
| Total Operating Income As Reported |
|
-14.75
+10.35%
|
-16.45
+48.50%
|
-31.95
-1.35%
|
-31.52
|
| EBITDA |
|
-4.36
+77.39%
|
-19.27
+30.89%
|
-27.88
+8.26%
|
-30.39
|
| Normalized EBITDA |
|
-13.17
+12.47%
|
-15.04
+49.57%
|
-29.83
-6.75%
|
-27.94
|
| Reconciled Depreciation |
|
1.63
-6.48%
|
1.74
-13.81%
|
2.02
+78.81%
|
1.13
|
| EBIT |
|
-5.99
+71.51%
|
-21.01
+29.74%
|
-29.90
+5.14%
|
-31.52
|
| Total Unusual Items |
|
8.81
+308.54%
|
-4.22
-316.75%
|
1.95
+179.61%
|
-2.45
|
| Total Unusual Items Excluding Goodwill |
|
8.81
+308.54%
|
-4.22
-316.75%
|
1.95
+179.61%
|
-2.45
|
| Special Income Charges |
|
-0.51
|
0.00
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
0.51
|
0.00
|
—
|
—
|
| Net Income |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Pretax Income |
|
-8.60
+61.63%
|
-22.41
+25.45%
|
-30.06
+11.34%
|
-33.91
|
| Net Non Operating Interest Income Expense |
|
-2.61
-86.70%
|
-1.40
-786.05%
|
-0.16
-219.08%
|
0.13
|
| Interest Expense Non Operating |
|
2.61
+86.70%
|
1.40
+786.05%
|
0.16
|
—
|
| Net Interest Income |
|
-2.61
-86.70%
|
-1.40
-786.05%
|
-0.16
-219.08%
|
0.13
|
| Interest Expense |
|
2.61
+86.70%
|
1.40
+786.05%
|
0.16
|
—
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
—
|
| Interest Income |
|
—
|
—
|
—
|
—
|
| Other Income Expense |
|
8.25
+281.00%
|
-4.56
-322.82%
|
2.05
+181.32%
|
-2.52
|
| Other Non Operating Income Expenses |
|
-0.56
-67.37%
|
-0.33
-445.20%
|
0.10
+243.76%
|
-0.07
|
| Gain On Sale Of Security |
|
9.32
+320.62%
|
-4.22
-316.75%
|
1.95
+179.61%
|
-2.45
|
| Tax Provision |
|
-0.40
+76.29%
|
-1.69
-107.81%
|
-0.81
+25.52%
|
-1.09
|
| Tax Rate For Calcs |
|
0.00
-37.71%
|
0.00
+179.47%
|
0.00
-15.63%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.41
+229.90%
|
-0.32
-705.75%
|
0.05
+167.17%
|
-0.08
|
| Net Income Including Noncontrolling Interests |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Net Income From Continuing And Discontinued Operation |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Net Income Continuous Operations |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Normalized Income |
|
-16.59
+1.30%
|
-16.81
+46.01%
|
-31.14
-2.30%
|
-30.44
|
| Net Income Common Stockholders |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Diluted EPS |
|
-0.13
+65.79%
|
-0.38
+41.54%
|
-0.65
+12.90%
|
-0.75
|
| Basic EPS |
|
-0.13
+65.79%
|
-0.38
+41.54%
|
-0.65
+12.90%
|
-0.75
|
| Basic Average Shares |
|
62.23
+14.32%
|
54.43
+21.90%
|
44.66
+1.98%
|
43.79
|
| Diluted Average Shares |
|
62.23
+14.32%
|
54.43
+21.90%
|
44.66
+1.98%
|
43.79
|
| Diluted NI Availto Com Stockholders |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Total Other Finance Cost |
|
—
|
—
|
0.16
+219.08%
|
-0.13
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
44.18
-6.73%
|
47.37
-10.55%
|
52.96
-16.25%
|
63.23
|
| Current Assets |
|
20.63
-4.49%
|
21.60
-14.94%
|
25.40
-24.77%
|
33.76
|
| Cash Cash Equivalents And Short Term Investments |
|
6.25
+90.52%
|
3.28
-76.79%
|
14.13
-36.19%
|
22.14
|
| Cash And Cash Equivalents |
|
6.25
+90.52%
|
3.28
-76.79%
|
14.13
-36.19%
|
22.14
|
| Receivables |
|
7.55
+3.14%
|
7.32
+20.85%
|
6.06
+6.92%
|
5.66
|
| Accounts Receivable |
|
7.55
+3.14%
|
7.32
+20.85%
|
6.06
+6.92%
|
5.66
|
| Gross Accounts Receivable |
|
7.71
+3.16%
|
7.48
+22.45%
|
6.11
+6.37%
|
5.74
|
| Allowance For Doubtful Accounts Receivable |
|
-0.16
-3.80%
|
-0.16
-218.14%
|
-0.05
+34.69%
|
-0.08
|
| Inventory |
|
5.28
+93.23%
|
2.73
-19.04%
|
3.38
-2.48%
|
3.46
|
| Raw Materials |
|
0.75
+31.75%
|
0.57
-16.89%
|
0.69
+11.81%
|
0.61
|
| Work In Process |
|
1.01
+101.59%
|
0.50
-40.04%
|
0.84
-34.48%
|
1.28
|
| Finished Goods |
|
3.53
+112.53%
|
1.66
-10.33%
|
1.85
+18.07%
|
1.57
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.00
-100.00%
|
5.00
|
0.00
|
—
|
| Other Current Assets |
|
1.55
-52.49%
|
3.27
+78.31%
|
1.83
-26.28%
|
2.49
|
| Total Non Current Assets |
|
23.55
-8.62%
|
25.77
-6.49%
|
27.56
-6.49%
|
29.47
|
| Net PPE |
|
18.75
-8.61%
|
20.51
-7.25%
|
22.12
-5.28%
|
23.35
|
| Gross PPE |
|
23.89
-3.42%
|
24.74
-1.64%
|
25.15
-0.37%
|
25.24
|
| Accumulated Depreciation |
|
-5.15
-21.77%
|
-4.23
-39.19%
|
-3.04
-60.07%
|
-1.90
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
6.66
-4.09%
|
6.95
+1.13%
|
6.87
+6.67%
|
6.44
|
| Other Properties |
|
10.92
-5.10%
|
11.51
-4.54%
|
12.06
-4.32%
|
12.60
|
| Leases |
|
6.31
+0.40%
|
6.28
+0.93%
|
6.22
+0.38%
|
6.20
|
| Goodwill And Other Intangible Assets |
|
3.23
-13.30%
|
3.72
-4.75%
|
3.91
-11.02%
|
4.39
|
| Other Intangible Assets |
|
3.23
-13.30%
|
3.72
-4.75%
|
3.91
-11.02%
|
4.39
|
| Non Current Prepaid Assets |
|
—
|
0.02
-56.50%
|
0.05
+10.95%
|
0.05
|
| Other Non Current Assets |
|
1.57
+2.67%
|
1.53
+3.37%
|
1.48
-12.06%
|
1.69
|
| Total Liabilities Net Minority Interest |
|
38.28
+5.55%
|
36.27
+23.04%
|
29.48
+5.81%
|
27.86
|
| Current Liabilities |
|
9.71
-1.18%
|
9.82
-30.00%
|
14.04
+44.48%
|
9.71
|
| Payables And Accrued Expenses |
|
7.93
-1.53%
|
8.05
-8.37%
|
8.79
+8.66%
|
8.09
|
| Payables |
|
2.87
-14.10%
|
3.34
-12.16%
|
3.80
+51.73%
|
2.51
|
| Accounts Payable |
|
2.87
-14.10%
|
3.34
-12.16%
|
3.80
+51.73%
|
2.51
|
| Other Payable |
|
—
|
—
|
—
|
0.02
|
| Current Accrued Expenses |
|
5.06
+7.38%
|
4.71
-5.48%
|
4.99
-10.67%
|
5.58
|
| Current Debt And Capital Lease Obligation |
|
0.54
+19.43%
|
0.45
-84.24%
|
2.87
+2537.84%
|
0.11
|
| Current Debt |
|
—
|
—
|
2.50
|
—
|
| Other Current Borrowings |
|
—
|
—
|
2.50
|
—
|
| Current Capital Lease Obligation |
|
0.54
+19.43%
|
0.45
+21.24%
|
0.37
+242.98%
|
0.11
|
| Current Deferred Liabilities |
|
0.33
-51.39%
|
0.68
-50.54%
|
1.38
-8.96%
|
1.52
|
| Current Deferred Revenue |
|
0.33
-51.39%
|
0.68
-50.54%
|
1.38
-8.96%
|
1.52
|
| Other Current Liabilities |
|
0.91
+42.52%
|
0.64
-35.96%
|
0.99
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
28.57
+8.06%
|
26.44
+71.25%
|
15.44
-14.90%
|
18.14
|
| Long Term Debt And Capital Lease Obligation |
|
28.57
+8.06%
|
26.44
+71.25%
|
15.44
-14.90%
|
18.14
|
| Long Term Debt |
|
16.67
+19.08%
|
14.00
+450.40%
|
2.54
-49.14%
|
5.00
|
| Long Term Capital Lease Obligation |
|
11.90
-4.35%
|
12.44
-3.51%
|
12.90
-1.87%
|
13.14
|
| Stockholders Equity |
|
5.90
-46.85%
|
11.11
-52.70%
|
23.48
-33.62%
|
35.37
|
| Common Stock Equity |
|
5.90
-46.85%
|
11.11
-52.70%
|
23.48
-33.62%
|
35.37
|
| Capital Stock |
|
0.06
+14.55%
|
0.06
+1.40%
|
0.05
+24.30%
|
0.04
|
| Common Stock |
|
0.06
+14.55%
|
0.06
+1.40%
|
0.05
+24.30%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
62.80
+13.98%
|
55.10
+1.09%
|
54.51
+24.30%
|
43.85
|
| Ordinary Shares Number |
|
62.80
+13.98%
|
55.10
+1.09%
|
54.51
+24.30%
|
43.85
|
| Additional Paid In Capital |
|
321.02
+3.29%
|
310.81
+1.51%
|
306.19
+6.69%
|
287.00
|
| Retained Earnings |
|
-312.21
-2.70%
|
-304.01
-7.31%
|
-283.29
-11.53%
|
-254.00
|
| Gains Losses Not Affecting Retained Earnings |
|
-2.98
-170.01%
|
4.25
+703.29%
|
0.53
-77.27%
|
2.33
|
| Other Equity Adjustments |
|
-2.98
-170.01%
|
4.25
+703.29%
|
0.53
-77.27%
|
2.33
|
| Total Equity Gross Minority Interest |
|
5.90
-46.85%
|
11.11
-52.70%
|
23.48
-33.62%
|
35.37
|
| Total Capitalization |
|
22.57
-10.09%
|
25.10
-3.54%
|
26.02
-35.54%
|
40.37
|
| Working Capital |
|
10.93
-7.25%
|
11.78
+3.66%
|
11.36
-52.74%
|
24.05
|
| Invested Capital |
|
22.57
-10.09%
|
25.10
-11.99%
|
28.52
-29.35%
|
40.37
|
| Total Debt |
|
29.11
+8.25%
|
26.89
+46.85%
|
18.31
+0.34%
|
18.25
|
| Net Debt |
|
10.42
-2.78%
|
10.72
|
—
|
—
|
| Capital Lease Obligations |
|
12.44
-3.51%
|
12.90
-2.81%
|
13.27
+0.15%
|
13.25
|
| Net Tangible Assets |
|
2.68
-63.76%
|
7.39
-62.27%
|
19.57
-36.82%
|
30.98
|
| Tangible Book Value |
|
2.68
-63.76%
|
7.39
-62.27%
|
19.57
-36.82%
|
30.98
|
| Interest Payable |
|
—
|
—
|
0.03
+519.94%
|
0.01
|
| Inventories Adjustments Allowances |
|
-0.01
|
0.00
|
—
|
—
|
| Other Inventories |
|
—
|
-0.30
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.38
+14.22%
|
-14.43
+33.37%
|
-21.66
+23.30%
|
-28.23
|
| Cash Flow From Continuing Operating Activities |
|
-12.38
+14.22%
|
-14.43
+33.37%
|
-21.66
+23.30%
|
-28.23
|
| Net Income From Continuing Operations |
|
-8.20
+60.43%
|
-20.72
+29.16%
|
-29.25
+10.87%
|
-32.81
|
| Depreciation Amortization Depletion |
|
1.63
-6.48%
|
1.74
-13.81%
|
2.02
+78.81%
|
1.13
|
| Depreciation |
|
1.37
-9.28%
|
1.51
-25.42%
|
2.02
+78.81%
|
1.13
|
| Amortization Cash Flow |
|
0.26
+11.49%
|
0.23
|
—
|
—
|
| Depreciation And Amortization |
|
1.63
-6.48%
|
1.74
-13.81%
|
2.02
+78.81%
|
1.13
|
| Amortization Of Intangibles |
|
0.26
+11.49%
|
0.23
|
—
|
—
|
| Other Non Cash Items |
|
0.82
+66.67%
|
0.49
+1048.00%
|
0.04
|
—
|
| Stock Based Compensation |
|
2.77
-26.46%
|
3.76
-9.51%
|
4.16
+9.35%
|
3.80
|
| Asset Impairment Charge |
|
0.96
+112.92%
|
0.45
-33.00%
|
0.67
+6.83%
|
0.63
|
| Operating Gains Losses |
|
-9.32
-320.62%
|
4.22
+316.75%
|
-1.95
-175.53%
|
2.58
|
| Net Foreign Currency Exchange Gain Loss |
|
-9.32
-320.62%
|
4.22
+316.75%
|
-1.95
-179.61%
|
2.45
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Change In Working Capital |
|
-1.03
+76.48%
|
-4.38
-265.30%
|
2.65
+174.38%
|
-3.56
|
| Change In Receivables |
|
0.42
+124.59%
|
-1.72
-600.28%
|
-0.25
+80.94%
|
-1.29
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
-1.29
|
| Change In Inventory |
|
-2.54
-608.00%
|
0.50
+172.82%
|
0.18
-80.61%
|
0.95
|
| Change In Prepaid Assets |
|
1.79
+232.47%
|
-1.35
-222.45%
|
1.10
+5076.64%
|
-0.02
|
| Change In Payables And Accrued Expense |
|
-0.71
+60.95%
|
-1.81
-212.48%
|
1.61
+149.47%
|
-3.25
|
| Change In Other Current Assets |
|
0.00
+100.00%
|
0.00
+2140.82%
|
-0.00
-100.09%
|
0.05
|
| Investing Cash Flow |
|
-0.41
+37.97%
|
-0.67
+28.54%
|
-0.94
+85.50%
|
-6.46
|
| Cash Flow From Continuing Investing Activities |
|
-0.41
+37.97%
|
-0.67
+28.54%
|
-0.94
+85.50%
|
-6.46
|
| Net PPE Purchase And Sale |
|
-0.09
+69.01%
|
-0.28
+47.22%
|
-0.54
+91.16%
|
-6.09
|
| Purchase Of PPE |
|
-0.16
+42.25%
|
-0.28
+47.22%
|
-0.54
+91.16%
|
-6.09
|
| Sale Of PPE |
|
0.08
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.49
+26.61%
|
-0.67
+28.54%
|
-0.94
+85.50%
|
-6.46
|
| Net Intangibles Purchase And Sale |
|
-0.33
+15.06%
|
-0.39
+3.30%
|
-0.40
-8.12%
|
-0.37
|
| Purchase Of Intangibles |
|
-0.33
+15.06%
|
-0.39
+3.30%
|
-0.40
-8.12%
|
-0.37
|
| Financing Cash Flow |
|
9.31
-0.24%
|
9.33
-35.53%
|
14.47
+191.84%
|
4.96
|
| Cash Flow From Continuing Financing Activities |
|
9.31
-0.24%
|
9.33
-35.53%
|
14.47
+191.84%
|
4.96
|
| Net Issuance Payments Of Debt |
|
2.48
-75.22%
|
10.00
|
0.00
-100.00%
|
5.00
|
| Issuance Of Debt |
|
2.48
-83.48%
|
15.00
|
0.00
-100.00%
|
5.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-5.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
2.48
-83.48%
|
15.00
|
0.00
-100.00%
|
5.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-5.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
2.48
-75.22%
|
10.00
|
0.00
-100.00%
|
5.00
|
| Net Common Stock Issuance |
|
5.39
+2912.29%
|
0.18
-98.74%
|
14.26
+35423.68%
|
-0.04
|
| Common Stock Payments |
|
—
|
—
|
—
|
-0.04
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
-0.04
|
| Proceeds From Stock Option Exercised |
|
1.44
|
0.00
-100.00%
|
0.22
|
0.00
|
| Net Other Financing Charges |
|
—
|
-0.85
|
—
|
—
|
| Changes In Cash |
|
-3.48
+39.59%
|
-5.77
+28.97%
|
-8.12
+72.70%
|
-29.73
|
| Effect Of Exchange Rate Changes |
|
1.49
+1852.94%
|
-0.09
+14.80%
|
-0.10
+62.05%
|
-0.26
|
| Beginning Cash Position |
|
9.76
-37.47%
|
15.62
-34.48%
|
23.83
-55.72%
|
53.83
|
| End Cash Position |
|
7.77
-20.41%
|
9.76
-37.47%
|
15.62
-34.48%
|
23.83
|
| Free Cash Flow |
|
-12.87
+14.76%
|
-15.10
+33.17%
|
-22.59
+34.88%
|
-34.69
|
| Interest Paid Supplemental Data |
|
2.08
+61.40%
|
1.29
+242.48%
|
0.38
|
0.00
|
| Common Stock Issuance |
|
5.39
+2912.29%
|
0.18
-98.74%
|
14.26
|
—
|
| Issuance Of Capital Stock |
|
5.39
+2912.29%
|
0.18
-98.74%
|
14.26
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 10-K2026-03-30 View
- 8-K2026-03-25 View
- 42025-11-20 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 8-K2025-10-03 View
- 8-K2025-09-16 View
- 8-K2025-08-20 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 42025-08-08 View
- 8-K2025-08-07 View
- 10-Q2025-08-07 View
- 8-K2025-08-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|